|
|
 |
|
Viewing report
|
|
|
|
Pharma Market Authorization Strategies: A Guide To Launching Drugs Quickly And Efficiently In Europe
Business Insights, Feb 2003, Pages: 133
Launching a drug in Europe can be an extremely costly and time-consuming procedure.
Although the centralized procedure is gaining ground as the one-stop shop for a EU-wide marketing authorization, its use is restricted to NCEs and biotechnology products.
The majority of marketing authorizations are still issued by national competent authorities through the mutual recognition procedure.
Pharma Market Authorization Strategies: A guide to launching drugs quickly and efficiently in Europe is a practical guide to speeding the process of launching drugs in the European market, deciding where to market first and how to build and retain market share post-authorization.
This report analyzes current trends and investigates future perspectives predicted by key decision makers.
Guiding the reader through the European Medicines Evaluation Agency's centralized procedure, the report combines insider opinions and the latest data to identify which Reference Member States are the fastest, cheapest and most efficient for NCEs and generics.
Customers who bought this item also bought
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2011 Edition
Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
New Drug Approval in the European Union
EU Paediatric Medicines Regulation: Boon or Burden?
The Pharmaceutical Market: Malta
Pharmaceutical Regulatory Affairs in the EU & US
Drug Safety in the Post-Vioxx Era: New Legislation, Regulation and Company Strategies in Europe and the US
The European Generics Outlook: A Country-By-Country Analysis Of Developing Market Opportunities And Revenue Defense Strategies
Orphan Drugs in Asia-Pacific: From Designation to Pricing, Funding & Market Access
Prescription Drugs - Global Strategic Business Report
|
|
|
|
